1. Home
  2. FATE vs IDE Comparison

FATE vs IDE Comparison

Compare FATE & IDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FATE
  • IDE
  • Stock Information
  • Founded
  • FATE 2007
  • IDE 2010
  • Country
  • FATE United States
  • IDE United States
  • Employees
  • FATE N/A
  • IDE N/A
  • Industry
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • IDE Finance/Investors Services
  • Sector
  • FATE Health Care
  • IDE Finance
  • Exchange
  • FATE Nasdaq
  • IDE Nasdaq
  • Market Cap
  • FATE 177.7M
  • IDE 172.8M
  • IPO Year
  • FATE 2013
  • IDE N/A
  • Fundamental
  • Price
  • FATE $1.18
  • IDE $11.38
  • Analyst Decision
  • FATE Hold
  • IDE
  • Analyst Count
  • FATE 7
  • IDE 0
  • Target Price
  • FATE $3.83
  • IDE N/A
  • AVG Volume (30 Days)
  • FATE 2.0M
  • IDE 33.5K
  • Earning Date
  • FATE 08-12-2025
  • IDE 01-01-0001
  • Dividend Yield
  • FATE N/A
  • IDE 8.83%
  • EPS Growth
  • FATE N/A
  • IDE N/A
  • EPS
  • FATE N/A
  • IDE N/A
  • Revenue
  • FATE $13,335,000.00
  • IDE N/A
  • Revenue This Year
  • FATE N/A
  • IDE N/A
  • Revenue Next Year
  • FATE N/A
  • IDE N/A
  • P/E Ratio
  • FATE N/A
  • IDE N/A
  • Revenue Growth
  • FATE 105.85
  • IDE N/A
  • 52 Week Low
  • FATE $0.66
  • IDE $8.61
  • 52 Week High
  • FATE $5.92
  • IDE $10.46
  • Technical
  • Relative Strength Index (RSI)
  • FATE 46.59
  • IDE 60.83
  • Support Level
  • FATE $1.16
  • IDE $11.36
  • Resistance Level
  • FATE $1.32
  • IDE $11.48
  • Average True Range (ATR)
  • FATE 0.16
  • IDE 0.07
  • MACD
  • FATE -0.04
  • IDE -0.03
  • Stochastic Oscillator
  • FATE 8.33
  • IDE 60.71

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.

Share on Social Networks: